Daptomycin - A novel antibiotic against Gram-positive pathogens

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 11, 2004, Pages 2321-2331

  LaPlante, Kerry L ^a   Rybak, Michael J ^b  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Bactericidal; Complicated skin and soft tissue infections; Daptomysin; Gram positive; Lipopeptide; Methicillin resistant; Staphylococcus aureus

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; CEFTRIAXONE; CEPHALOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; HABEKACIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LINEZOLID; METICILLIN; METRONIDAZOLE; NAFCILLIN; PENICILLIN G; PROBENECID; RIFAMPICIN; TOBRAMYCIN; VANCOMYCIN; WARFARIN;

ANAEROBIC CAPACITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTHRALGIA; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BURN INFECTION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; DIABETIC FOOT; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DYSPEPSIA; DYSPNEA; FEMALE; FEVER; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION SITE; INJECTION SITE REACTION; INSOMNIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIMB PAIN; LIVER DYSFUNCTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA AND VOMITING; NONHUMAN; POSTANTIBIOTIC EFFECT; POSTOPERATIVE INFECTION; PRURITUS; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS GROUP C; STREPTOCOCCUS GROUP G; STREPTOCOCCUS PYOGENES; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; URINARY TRACT INFECTION; URTICARIA;

ANIMALS; ANTI-BACTERIAL AGENTS; CONTROLLED CLINICAL TRIALS; DAPTOMYCIN; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 8544232151     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.11.2321     Document Type: Review

References (65)

1. [no authors listed] Staphylococcus aureus resistant to vancomycin-United States. MMWR Morb. Mortal. Wkly. Rep. (2002) 51:565-567.
2. [no authors listed] Vancomycin-resistant Staphylococcus aureus-Pennsylvania. MMWR Morb. Mortal Wkly. Rep. (2002) 51 902.
3. MCHENNEY MA, HOSTED TJ, DEHOFF BS, ROSTECK PR Jr, BALTZ RH: Molecular cloning and physical mapping of the daptomycin gene cluster from Streptomyces roseosporus. J. Bacteriol. (1998) 180: 43-151.
4. DEBONO M, ABBOTT BJ, MOLLOY RM et al.: Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). J. Antibiot. (Tokyo) (1988) 41:1093-1105.
5. SILVERMAN JA, OLIVER N, ANDREW T, LI T: Resistance studies with daptomycin. Antimicrob. Agents Chemother. (2001) 45: 799-1802.
6. SILVERMAN JA, PERLMUTTER NG, SHAPIRO HM: Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. (2003) 47: 538-2544.
7. ALBORN WE Jr, ALLEN NE, PRESTON DA: Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob. Agents Chemother. (1991) 35:2282-2287.
8. BOARETTI M, CANEPARI P, LLEO MM, SATTA G: The activity of daptomycin on Enterococcus faecium protoplasts: indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis. J. Antimicrob. Chemother. (1993) 31:227-235.
9. CANEPARI P, FONTANA R, SATTA G: New targets for the mechanism of action of antibiotics active against Gram-positive cocci. J. Chemother. (1991) 3(Suppl. 1):141-143.
10. BARRY AL, FUCHS PC, BROWN SD: In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. (2001) 45:1919-1922.
11. CRITCHLEY IA, DRAGHI DC, SAHM DF, THORNSBERRY C, JONES ME, KARLOWSKY JA: Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J. Antimicrob. Chemother. (2003) 51: 39-649.
12. FUCHS PC, BARRY AL, BROWN SD: In vitro bactericidal activity of daptomycin against staphylococci. J. Antimicrob. Chemother. (2002) 49:467-470.
13. KING A, PHILLIPS I: The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J. Antimicrob. Chemother. (2001) 48:219-223.
14. PETERSEN PJ, BRADFORD PA, WEISS WJ et al.: In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob. Agents Chemother. (2002) 46:2595-2601.
15. SNYDMAN DR, JACOBUS NV, MCDERMOTT LA, LONKS JR, BOYCE JM: Comparative in vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens. Antimicrob. Agents Chemother. (2000) 44:3447-3450.
16. TEDESCO KL AND RYBAK MJ: In vitro activities of daptomycin, arbekacin and tigecycline (GAR-936) against several clinical glycopeptide-intermediate Staphylococcus species. 41st Annual Infectious Diseases Society of America (IDSA), San Diago, USA (2003) (Abstract 179).
17. WISE R, ANDREWS JM, ASHBY JP: Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J. Antimicrob. Chemother. (2001) 48:563-567.
18. BEMER P, JUVIN ME, BRYSKIER A, DRUGEON H: In vitro Activities of a New Lipopeptide, HMR 1043, against Susceptible and Resistant Gram-Positive Isolates. Antimicrob. Agents Chemother. (2003) 47: 025-3029.
19. BOARETTI M, CANEPARI P: Purification of daptomycin binding proteins (DBPs) from the membrane of Enterococcus hirae. New Microbiol. (2000) 23:305-317.
20. AKINS RL, RYBAK MJ: Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. (2001) 45:454-459.
21. AKINS RL, RYBAK MJ: In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob. Agents Chemother. (2000) 44:1925-1929.
22. CHA R, BROWN WJ, RYBAK MJ: Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. (2003) 47:3960-3963.
23. CHANG S, SIEVERT DM, HAGEMAN JC et al.: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J Med. (2003) 348:1342-1347.
24. RYBAK MJ, HERSHBERGER E, MOLDOVAN T, GRUCZ RG: In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and resistant strains. Antimicrob. Agents Chemother. (2000) 44:1062-1066.
25. FUCHS PC, BARRY AL, BROWN SD:Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn. Microbiol. Infect. Dis. (2000) 38:51-58.
26. GOLDSTEIN EJ, CITRON DM, MERRIAM CV et al.: In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 Gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob. Agents Chemother. (2003) 47:337-341.
27. CAILLON J, JUVIN ME, PIRAULT JL, DRUGEON HB: Bactericidal effect of daptomycin (LY 146032) compared with vancomycine and teicoplanin against Gram-positive bacteria. Pathol. Biol. (Paris) (1989) 37:540-548.
28. BINGEN E, LAMBERT-ZECHOVSKY N, LECLERCQ R, DOIT C, MARIANI-KURKDJIAN P: Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium. J. Antimicrob. Chemother. (1990) 26:619-626.
29. BINGEN E, DOIT C, LAMBERT-ZECHOVSKY N et al.: Bactericidal activity of daptomycin against vancomycin-resistant Enterococcus faecium in an in vitro pharmacokinetic model. Eur. J. Clin. Microbiol. Infect. Dis. (1991) 10:1062-1065.
30. CHA R, GRUCZ JR Jr, RYBAK MJ: Daptomycin dose-effect relationship against resistant Gram-positive organisms. Antimicrob. Agents Chemother. (2003) 47:1598-1603.
31. TEDESCO KL, RYBAK MJ: Impact of high inoculum Staphylcocccus aureus on the activities of nafcillin, vancomycin, linezolid, gentamicin and dapromycin in an in vitro pharmacodynamic model. 43rd Interscience Conference on Antimicrobial Agents of Chemotherapy September 14 - 17 (2003).
32. LAMP KC, RYBAK MJ, BAILEY EM, KAATZ GW: In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob. Agents Chemother. (1992) 36:2709-2714.
33. LAMP KC, RYBAK MJ: Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium. Antimicrob. Agents Chemother. (1993) 37:605-609.
34. MACKENZIE FM, GOULD IM: The post-antibiotic effect. J. Antimicrob. Chemother. (1993) 32:519-537.
35. PANKUCH GA, JACOBS MR, APPELBAUM PC: Postantibiotic Effects of Daptomycin against 14 Staphylococcal and Pneumococcal. Antimicrob. Agents Chemother. (2003) 47:3012-3014.
36. BUSH LM, BOSCIA JA, WENDELER M, PITSAKIS PG, KAYE D: In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob. Agents Chemother. (1989) 33:1198-1200.
37. HANBERGER H, NILSSON LE, MALLER R, ISAKSSON B: Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob. Agents Chemother. (1991) 35:1710-1716.
38. RAND KH, HOUCK H: Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J. Antimicrob. Chemother. (2004) 53:530-532.
39. BRYANT RE, MAZZA JA, GARDNER EM: Effect of abscess milieu on bactericidal activity of LY146032 against staphylococci. Eur. J. Clin. Microbiol (1987) 6:186-188.
40. LOUIE A, BALTCH AL, RITZ WJ, SMITH RP, ASPERILLA M: Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci. Chemotherapy (1993) 39:302-309.
41. DUEZ JM, PECHINOT A, SIEBOR E, CORDIN X, KAZMIERCZAK A: Bactericidal activity of daptomycin and vancomycin alone or in combination with tobramycin, netilmicin or ampicillin against enterococcus. Pathol. Biol. (Paris) (1989) 37:263-268.
42. EL MADY A, MORTENSEN JE: The bactericidal activity of ampicillin, daptomycin, and vancomycin against ampicillin-resistant Enterococcus faecium. Diagn. Microbiol. Infect. Dis. (1991) 14: 41-145.
43. SAPICO FL, GINUNAS VJ, CANAWATI HN, MONTGOMERIE JZ: LY146032, alone and in combination with gentamicin, for the treatment of enterococcal pyelonephritis in the rat model. Antimicrob. Agents Chemother. (1988) 32:81-83.
44. WATANAKUNAKORN C: In-vitro activity of LY 146032, a novel cyclic lipopeptide, alone and in combination with gentamicin or tobramycin against enterococci. J. Antimicrob. Chemother. (1987) 19:445-448.
45. LOUIE A, KAW P, LIU W, JUMBE N, MILLER MH, DRUSANO GL: Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. (2001) 45: 45-851.
46. DANDEKAR PK, TESSIER PR, WILLIAMS P, NIGHTINGALE CH, NICOLAU DP: Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J. Antimicrob. Chemother. (2003) 52:405-411.
47. SAFDAR N, ANDES D, CRAIG WA: In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. (2004) 48:63-68.
48. OLESON FB Jr, BERMAN CL, KIRKPATRICK JB et al.: Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob. Agents Chemother. (2000) 44:2948-2953.
49. RYBAK MJ, MCKINNON P. CHA R, DVORCHIK BH: Daptomycin Pharmacodynamcis (PD) versus MRSA at Various Doses as Assessed by a Monte Carlo Prediction Model. 41st Interscience Conference on Antimicrobial Agents of Chemotherapy (2001) [Abstract 2195].
50. KAATZ GW, SEO SM, REDDY VN, BAILEY EM, RYBAK MJ: Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. (1990) 34:2081-2085.
51. Eli Lilly & Company. Daptomycin Clinical Investigators Newsletter (1990).
52. KAATZ GW, SEO SM: Analysis of the Mechanism(s) of Daptomycin Resistance in Staphylococcus aureus. 41st Interscience Conference on Antimicrobial Agents of Chemotherapy (2001) [Abstract C1-1803].
53. RYBAK MJ, BAILEY EM, LAMP KC, KAATZ GW. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for Gram-positive endocarditis and bacteremia. Antimicrob. Agents Chemother. (1992) 36:1109-1114.
54. LEE BL, SACHDEVA M, CHAMBERS HF: Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob. Agents Chemother. (1991) 35:2505-2508.
55. WISE R, GEE T, ANDREWS JM, DVORCHIK B, MARSHALL G: Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob. Agents Chemother. (2002) 46:31-33.
56. DVORCHIK BH, BRAZIER D, DEBRUIN MF, ARBEIT RD: Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy Subjects. Antimicrob. Agents Chemother. (2003) 47:1318-1323.
57. SICA DA, GEHR T, AND DVORCHIK BH: Pharmacokinetics and Safety of single-dose daptomycin in subjects with graded renal insufficiency and end stage renal disease. 42nd Interscience Conference on Antimicrob. Agents Chemother. (2002) [Abstract 2257].
58. DVORCHIK B: Moderate liver impairment has no influence on daptomycin pharmacokinetics. J. Clin. Pharmacol. (2004) 44: 15-722.
59. DVORCHIK BH, DAMPHOUSSE D: The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched non-obese subjects. J. Clin. Pharmacol. (2004).
60. DVORCHIK B, ARBEIT R, CHUNG J et al.: Population pharmacokinetics of daptomycin. Antimicrob. Agents Chemother. (2004) 48(8):2799-2807.
61. DVORCHIK B, DAMPHOUSSE D: Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers. J. Clin. Pharmacol. (2004) 44:612-620.
62. ARBEIT RD, MAKI D, TALLY FP, CAMPANARO E, EISENSTEIN BI: The safety and efficacy of dapromycin for the treatment of complicated skin and skin-structure infections. Clin Infect. Dis. (2004) 38: 673-1681.
63. ALDER J, ARBEIT R, EISENSTEINE B: Pulmonary epithelial lining fluid (EFL) as a privileged site:daptomycin in pulmonary infections. International Conference on Infectious Diseases. Cancun, Mexico (2004).
64. TRACZEWSKI MM, BROWN SD, BERRY AL: Evaluation of daptomycin susceptibility by the E-test method using E-test strips with added calcium. 42nd Interscience Conference on Antimicrobial Agents of Chemotherapy (2002).
65. TEDESCO KL, RYBAK MJ: Daptomycin. Pharmacotherapy (2004) 24:41-57.